Skip to content
MARKETS / NASDAQ / CYTK
NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP

Cytokinetics Inc. CYTK

19 fiscal years on record · USD · FY2025 reported · SEC filings only
$88.0M
▲ 376.6% YoY
$-785.0M
$-534.8M
In brief

What this company does

The company's first commercial product is MYQORZO (aficamten), 5 mg, 10 mg, 15 mg and 20 mg tablets, which the FDA approved in December 2025. With the approval of MYQORZO, the company has transitioned into a fully-integrated specialty biopharmaceutical company. All of the company's research and development activities relate to the biology of muscle function and have evolved from its knowledge and expertise regarding the cytoskeleton, a complex biological infrastructure that plays a fundamental role within every human cell. As of December 31, 2025, Cytokinetics had 673 employees. Behind MYQORZO, the company is making disciplined pipeline investments in investigational products that are at discovery, preclinical and clinical stages of research and development.

Written from the business description in CYTOKINETICS, INCORPORATED's annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.

Growth
USD 88.0M
Revenue, FY2025 · full 19-year series below
Revenue $M Net income $M
FY2025 · Revenue 88.0 · Net income -785.0
40M80M-400M2007201020132016201920222025
Compound annual growth
−2.4%
+9.5%
+11.9%
+26.5%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +9.5% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−892 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -695.4% · Net -891.6%
-2000%-4000%-6000%2007201020132016201920222025
ROE
FY2022 · ROE -572.1%
-500%-1000%-1500%2007201020132016201920222025

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -534.8
-200M-400M2007201020132016201920222025

Total assetsUSD 1.4B
EquityUSD -659.6M
CashUSD 122.5M
Gross debtUSD 287.6M
Net debtUSD 165.0M
Current ratio4.53×

Equity was negative — liabilities exceeded assets. No ratio is shown.

The 19-year record
19 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010200920082007
Revenue $B0.10.00.00.10.10.10.00.00.00.10.00.00.00.00.00.00.1··
Operating income $B−0.6−0.5−0.5−0.3−0.2−0.1−0.1−0.1−0.10.0−0.0−0.0−0.0−0.0−0.0−0.00.0··
EBITDA $B−0.6−0.5−0.5−0.3−0.2−0.1−0.1−0.1−0.10.0−0.0−0.0−0.0−0.0−0.0−0.00.0··
Income tax $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0−0.00.0··
Net income $B−0.8−0.6−0.5−0.4−0.2−0.1−0.1−0.1−0.10.0−0.0−0.0−0.0−0.0−0.0−0.00.0−0.1−0.0
Free cash flow $B−0.5−0.4−0.4−0.3−0.2−0.0−0.1−0.1−0.10.00.0−0.0−0.0−0.0−0.0−0.00.0··
EPS, diluted $−6.54−5.26−5.45−4.33−2.80−1.97−2.11−1.95−2.590.39−0.97−0.41−1.24−2.30−4.30−0.770.42··
Dividend / sh $···················
Payout %···················
ROE %···−572.1−120.5−248.5−1622.9−156.6−125.220.2−46.7−20.0−54.2−68.3−80.6−57.332.5−75.3−48.9
Shares out B0.120.120.100.090.080.070.060.050.050.040.040.040.030.020.070.07···

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 68 reconciliationsAUDITED

Reconciled in 19 of 19 fiscal years. 8 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated innot stated in the filings
Fiscal year endsDecember 31
Data on record since2007

Share this section

Download image